Should you buy Ramsay Health Care Limited shares today?

The Ramsay Health Care Limited (ASX: RHC) share price has been a bit of a disappointment over the last 12 months. During this time it has fallen by approximately 5.5%.

But according to one leading broker, now could be a good time to consider accumulating shares.

What has the broker said?

A note out of Ord Minnett this week reveals that its analysts have given the private hospital operator an accumulate rating with a slightly reduced $80.00 price target. For those that are unaware, an accumulate rating ranks between buy and hold ratings.

This price target implies potential upside of almost 20% for its shares over the next 12 months.

According to the note, the broker believes that its Australian operations will be the main driver of growth during the first-half of FY 2018 along with the benefits of its multi-year procurement savings program.

Overall, its analysts have forecast a 7% increase in Australian revenue despite the negative impact of cuts to prostheses prices. Ramsay is due to release its half-year result on February 28.

Should you invest?

Whilst I think that Ramsay is one of the best shares in the healthcare sector and a great buy and hold investment option, it may be prudent for investors to sit tight and wait to see how Ramsay’s first-half has been before hitting the buy button.

After all, with its shares trading at a premium to the market average, if its first-half falls short of expectations then its share price could take a tumble. This would of course present investors with an opportunity to buy shares at an even more attractive price.

If its result is solid and its outlook positive, I would suggest investors snap up shares ahead of industry peers Healthscope Ltd (ASX: HSO) and Primary Health Care Limited (ASX: PRY).

In the meantime, I think that these rapidly growing blue chip shares could be in the buy zone right now.

Top 3 ASX Blue Chips To Buy In 2018

For many, blue chip stocks mean stability, profitability and regular dividends, often fully franked..

But knowing which blue chips to buy, and when, can be fraught with danger.

The Motley Fool’s in-house analyst team has poured over thousands of hours worth of proprietary research to bring you the names of "The Motley Fool’s Top 3 Blue Chip Stocks for 2018."

Each one pays a fully franked dividend. Each one has not only grown its profits, but has also grown its dividend. One increased it by a whopping 33%, while another trades on a grossed up (fully franked) dividend yield of almost 7%.

The names of these Top 3 ASX Blue Chips are included in this specially prepared free report. But you will have to hurry. Depending on demand – and how quickly the share prices of these companies moves – we may be forced to remove this report.

Click here to claim your free report.

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia has recommended Ramsay Health Care Limited. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

The 5 mining stocks we’re recommending in 2019…

For decades, Australian mining companies have minted money for individual investors like you and me. But if you believe the pundits and talking heads on TV, those days are long gone. Finito! Behind us forever…

We say nothing could be further from the truth. To earn the really massive returns, you’ve got to fish where others aren’t fishing—and the mining sector could be primed for a resurgence. That’s why top Motley Fool analysts just revealed their exciting new research on 5 ASX miners they believe could help you profit in 2019 and beyond…


The best way we see to play the global zinc shortage… Our #1 favourite large-cap miner (hint: it’s not BHP)… one early-stage gold miner we think could hit the motherlode… Plus two more surprising companies you probably haven’t heard of yet!

For free access to our brand-new research, simply click here or the link below. But be warned, this research is available free for a limited time only, and we reserve the right to withdraw it at any time.

Click here for your FREE report!